EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

H.R. Hendriks, P.E. Pizao, D.P. Berger, K.L. Kooistra, M.C. Bibby, E. Boven, H.C. Dreef-Van der Meulen, R.E.C. Henrar, H.H. Fiebig, J.A. Double, H.W. Hornstra, H.M. Pinedo, P. Workman, G. Schwartsmann

Research output: Contribution to journalArticleAcademicpeer-review

32 Downloads (Pure)
Original languageEnglish
Pages (from-to)897-906
JournalEuropean Journal of Cancer
Volume29A
Issue number6
Publication statusPublished - 1993

Cite this

Hendriks, H. R., Pizao, P. E., Berger, D. P., Kooistra, K. L., Bibby, M. C., Boven, E., ... Schwartsmann, G. (1993). EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. European Journal of Cancer, 29A(6), 897-906.